NPPB and coronary artery disorder: Therefore, this study used FGR to predict the poor prognosisof CHD patients through the use of long-term follow-up to determine whether FGRcan predict the occurrence of major cardiac and cerebrovascular adverse events(MACCE), major adverse cardiovascular events (MACE), all-cause mortality (ACM)and cardiogenic mortality (CM) in CHD patients, by comparing our novel cardiacmarker FGR with traditional risk factors, such as NT-proBNP, to further improveclinical diagnosis and treatment.